---
document_datetime: 2026-02-17 11:58:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/arexvy.html
document_name: arexvy.html
version: success
processing_time: 0.1066039
conversion_datetime: 2026-02-21 12:26:00.634752
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
# Arexvy

[RSS](/en/individual-human-medicine.xml/67684)

##### Authorised

This medicine is authorised for use in the European Union

recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Arexvy](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76757)
- [More information on Arexvy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Arexvy is a vaccine used to protect adults 18 years of age and older against lower respiratory tract disease (LRTD, diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV).

Arexvy contains a version of a protein found on the surface of the virus called RSVPreF3.

Expand section

Collapse section

## How is Arexvy used?

The recommended dose is a single injection into a muscle, preferably into the muscle of the upper arm.

The vaccine can only be obtained with a prescription and should be used according to official recommendations issued at national level by public health bodies.

For more information about using Arexvy, see the package leaflet or contact your doctor or pharmacist.

## How does Arexvy work?

Arexvy works by preparing the immune system (the body's natural defences) to defend itself against a LRTD caused by RSV. Arexvy contains a protein from the surface of RSV. When a person is given the vaccine, the immune system treats the virus protein as 'foreign' and makes defences against it. If, later on, the vaccinated person comes into contact with the virus, the immune system will recognise the protein and be prepared to attack it. This will help to protect the person against LRTD caused by RSV.

## What benefits of Arexvy have been shown in studies?

In a study involving over 25,000 adults aged 60 years and above, people who received Arexvy had a 83% reduction in their risk of getting LRTD caused by RSV compared with those who had a dummy injection.

In the group that received Arexvy, 7 out of 12,466 people got LRTD, while in the group that received a dummy injection, 40 out of 12,494 people got the disease.

A second study involved 769 people aged 50 to 59 years (including 386 people at increased risk of LRTD caused by RSV). Following vaccination with Arexvy, the immune response in these people (as measured by the level of antibodies against RSV in the blood) was comparable to that seen in people 60 years old and above.

In a third study involving 426 people aged 18 to 49 years at increased risk of LRTD caused by RSV, the immune response triggered by Arexvy one month after vaccination was also comparable to that seen in people 60 years of age and older.

## What are the risks associated with Arexvy?

For the full list of side effects and restrictions with Arexvy, see the package leaflet.

The most common side effects with Arexvy (which may affect more than 1 in 10 people) include injection site pain, tiredness, muscle pain, headache and joint pain. These side effects are usually mild or moderate in intensity and resolve within a few days after vaccination.

## Why is Arexvy authorised in the EU?

Arexvy was found to be effective in preventing LRTD caused by RSV in people 60 years of age and older. By preventing LRTD caused by RSV, the vaccine is also expected to reduce the risk of severe RSV disease in these people. In addition, data in adults aged 18 to 49 years at increased risk of LRTD caused by RSV and in adults aged 50 to 59 years showed that Arexvy triggered an immune response comparable to that seen in people aged 60 years and above. There is no evidence that people at increased risk of LRTD respond differently to Arexvy than those not at increased risk of LRTD. The vaccine is therefore expected to provide protection against LRTD caused by RSV in adults aged 18 years and older. There are no serious safety concerns with Arexvy and the European Medicines Agency therefore decided that its benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Arexvy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Arexvy have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Arexvy are continuously monitored. Suspected side effects reported with Arexvy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Arexvy

Arexvy received a marketing authorisation valid throughout the EU on 06 June 2023.

Arexvy : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-38993

English (EN) (127.15 KB - PDF)

**First published:** 16/06/2023

**Last updated:** 17/02/2026

[View](/en/documents/overview/arexvy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-180)

български (BG) (155.11 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/bg/documents/overview/arexvy-epar-medicine-overview_bg.pdf)

español (ES) (124.55 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/es/documents/overview/arexvy-epar-medicine-overview_es.pdf)

čeština (CS) (148.15 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/cs/documents/overview/arexvy-epar-medicine-overview_cs.pdf)

dansk (DA) (122.52 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/da/documents/overview/arexvy-epar-medicine-overview_da.pdf)

Deutsch (DE) (128.94 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/de/documents/overview/arexvy-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.07 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/et/documents/overview/arexvy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.7 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/el/documents/overview/arexvy-epar-medicine-overview_el.pdf)

français (FR) (126.08 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/fr/documents/overview/arexvy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (150.04 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/hr/documents/overview/arexvy-epar-medicine-overview_hr.pdf)

italiano (IT) (124.6 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/it/documents/overview/arexvy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (143.8 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/lv/documents/overview/arexvy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.54 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/lt/documents/overview/arexvy-epar-medicine-overview_lt.pdf)

magyar (HU) (148.64 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/hu/documents/overview/arexvy-epar-medicine-overview_hu.pdf)

Malti (MT) (155.8 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/mt/documents/overview/arexvy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (125.76 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/nl/documents/overview/arexvy-epar-medicine-overview_nl.pdf)

polski (PL) (150.7 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/pl/documents/overview/arexvy-epar-medicine-overview_pl.pdf)

português (PT) (125.97 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/pt/documents/overview/arexvy-epar-medicine-overview_pt.pdf)

română (RO) (144.19 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/ro/documents/overview/arexvy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (147.69 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sk/documents/overview/arexvy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.91 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sl/documents/overview/arexvy-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.5 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/fi/documents/overview/arexvy-epar-medicine-overview_fi.pdf)

svenska (SV) (123.01 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sv/documents/overview/arexvy-epar-medicine-overview_sv.pdf)

Arexvy : EPAR - Risk management plan

English (EN) (708.22 KB - PDF)

**First published:** 09/10/2024

**Last updated:** 17/02/2026

[View](/en/documents/rmp/arexvy-epar-risk-management-plan_en.pdf)

## Product information

Arexvy : EPAR - Product Information

English (EN) (455.3 KB - PDF)

**First published:** 16/06/2023

**Last updated:** 17/02/2026

[View](/en/documents/product-information/arexvy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-277)

български (BG) (568.84 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/bg/documents/product-information/arexvy-epar-product-information_bg.pdf)

español (ES) (545.65 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/es/documents/product-information/arexvy-epar-product-information_es.pdf)

čeština (CS) (522.86 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/cs/documents/product-information/arexvy-epar-product-information_cs.pdf)

dansk (DA) (518.11 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/da/documents/product-information/arexvy-epar-product-information_da.pdf)

Deutsch (DE) (582.84 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/de/documents/product-information/arexvy-epar-product-information_de.pdf)

eesti keel (ET) (509.79 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/et/documents/product-information/arexvy-epar-product-information_et.pdf)

ελληνικά (EL) (570.51 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/el/documents/product-information/arexvy-epar-product-information_el.pdf)

français (FR) (506.84 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/fr/documents/product-information/arexvy-epar-product-information_fr.pdf)

hrvatski (HR) (507.85 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/hr/documents/product-information/arexvy-epar-product-information_hr.pdf)

íslenska (IS) (530.99 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/is/documents/product-information/arexvy-epar-product-information_is.pdf)

italiano (IT) (573.81 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/it/documents/product-information/arexvy-epar-product-information_it.pdf)

latviešu valoda (LV) (512 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/lv/documents/product-information/arexvy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (590.9 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/lt/documents/product-information/arexvy-epar-product-information_lt.pdf)

magyar (HU) (526.78 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/hu/documents/product-information/arexvy-epar-product-information_hu.pdf)

Malti (MT) (608.83 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/mt/documents/product-information/arexvy-epar-product-information_mt.pdf)

Nederlands (NL) (566.55 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/nl/documents/product-information/arexvy-epar-product-information_nl.pdf)

norsk (NO) (479.37 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/no/documents/product-information/arexvy-epar-product-information_no.pdf)

polski (PL) (563.88 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/pl/documents/product-information/arexvy-epar-product-information_pl.pdf)

português (PT) (521.88 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/pt/documents/product-information/arexvy-epar-product-information_pt.pdf)

română (RO) (548.02 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/ro/documents/product-information/arexvy-epar-product-information_ro.pdf)

slovenčina (SK) (496.94 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sk/documents/product-information/arexvy-epar-product-information_sk.pdf)

slovenščina (SL) (524.68 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sl/documents/product-information/arexvy-epar-product-information_sl.pdf)

Suomi (FI) (432.85 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/fi/documents/product-information/arexvy-epar-product-information_fi.pdf)

svenska (SV) (496.74 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

17/02/2026

[View](/sv/documents/product-information/arexvy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000276225 19/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Arexvy : EPAR - All authorised presentations

English (EN) (49.46 KB - PDF)

**First published:** 16/06/2023

[View](/en/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-586)

български (BG) (68.36 KB - PDF)

**First published:**

16/06/2023

[View](/bg/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.61 KB - PDF)

**First published:**

16/06/2023

[View](/es/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (80.24 KB - PDF)

**First published:**

16/06/2023

[View](/cs/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.87 KB - PDF)

**First published:**

16/06/2023

[View](/da/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.09 KB - PDF)

**First published:**

16/06/2023

[View](/de/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (59.9 KB - PDF)

**First published:**

16/06/2023

[View](/et/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.58 KB - PDF)

**First published:**

16/06/2023

[View](/el/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_el.pdf)

français (FR) (58.2 KB - PDF)

**First published:**

16/06/2023

[View](/fr/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (80.83 KB - PDF)

**First published:**

16/06/2023

[View](/hr/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.64 KB - PDF)

**First published:**

16/06/2023

[View](/is/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.44 KB - PDF)

**First published:**

16/06/2023

[View](/it/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.63 KB - PDF)

**First published:**

16/06/2023

[View](/lv/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.81 KB - PDF)

**First published:**

16/06/2023

[View](/lt/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (82.31 KB - PDF)

**First published:**

16/06/2023

[View](/hu/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (83.43 KB - PDF)

**First published:**

16/06/2023

[View](/mt/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.08 KB - PDF)

**First published:**

16/06/2023

[View](/nl/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (67.46 KB - PDF)

**First published:**

16/06/2023

[View](/no/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.1 KB - PDF)

**First published:**

16/06/2023

[View](/pl/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.68 KB - PDF)

**First published:**

16/06/2023

[View](/pt/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_pt.pdf)

română (RO) (76.48 KB - PDF)

**First published:**

16/06/2023

[View](/ro/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.77 KB - PDF)

**First published:**

16/06/2023

[View](/sk/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (67.64 KB - PDF)

**First published:**

16/06/2023

[View](/sl/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (60.03 KB - PDF)

**First published:**

16/06/2023

[View](/fi/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.79 KB - PDF)

**First published:**

16/06/2023

[View](/sv/documents/all-authorised-presentations/arexvy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Arexvy International non-proprietary name (INN) or common name recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E Therapeutic area (MeSH) Respiratory Syncytial Virus Infections Anatomical therapeutic chemical (ATC) code J07BX05

### Pharmacotherapeutic group

Other viral vaccines

### Therapeutic indication

Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 18 years of age and older.  The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/006054 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Opinion adopted 26/04/2023 Marketing authorisation issued 06/06/2023 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Arexvy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (205.21 KB - PDF)

**First published:** 10/09/2025

**Last updated:** 17/02/2026

[View](/en/documents/procedural-steps-after/arexvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Arexvy : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (143.25 KB - PDF)

**First published:** 23/02/2024

**Last updated:** 26/06/2025

[View](/en/documents/procedural-steps-after/arexvy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Arexvy-VR-0000276225 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMADOC-1700519818-2676030

English (EN) (2.36 MB - PDF)

**First published:** 17/02/2026

[View](/en/documents/variation-report/arexvy-vr-0000276225-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Arexvy (EMA/VR/0000276225)

Adopted

Reference Number: EMADOC-1700519818-2676032

English (EN) (124.05 KB - PDF)

**First published:** 11/12/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arexvy-ema-vr-0000276225_en.pdf)

Arexvy : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - PSUSA/00000031/202411

Reference Number: EMADOC-1700519818-2215766

English (EN) (184.05 KB - PDF)

**First published:** 10/09/2025

[View](/en/documents/scientific-conclusion/arexvy-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-psusa-00000031-202411_en.pdf)

Arexvy : EPAR - EMEA/H/C/PSUSA/00010438/202407  - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/62447/2025

English (EN) (94.07 KB - PDF)

**First published:** 23/05/2025

[View](/en/documents/scientific-conclusion/arexvy-epar-emea-h-c-psusa-00010438-202407-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Arexvy-H-C-006054-II-0008: EPAR - Assessment report

Adopted

Reference Number: EMA/354383/2024

English (EN) (2.94 MB - PDF)

**First published:** 09/10/2024

[View](/en/documents/variation-report/arexvy-h-c-006054-ii-0008-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of opinion for Arexvy (II-08)

Adopted

Reference Number: EMA/CHMP/304362/2024

English (EN) (137.07 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-arexvy-ii-08_en.pdf)

## Initial marketing authorisation documents

Arexvy : EPAR - Public assessment report

Adopted

Reference Number: EMA/227054/2023

English (EN) (1.53 MB - PDF)

**First published:** 16/06/2023

[View](/en/documents/assessment-report/arexvy-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Arexvy

Adopted

Reference Number: EMA/CHMP/141401/2023

English (EN) (88.93 KB - PDF)

**First published:** 26/04/2023

[View](/en/documents/smop-initial/chmp-summary-opinion-arexvy_en.pdf)

#### News on Arexvy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 December 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-december-2025) 12/12/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

[First vaccine to protect older adults from respiratory syncytial virus (RSV) infection](/en/news/first-vaccine-protect-older-adults-respiratory-syncytial-virus-rsv-infection) 26/04/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

#### More information on Arexvy

- [A post-marketing active surveillance study to evaluate the risk of Guillain-Barré syndrome, acute disseminated encephalomyelitis, and atrial fibrillation in adults 50 years and older vaccinated with GSK's Arexvy vaccine in the United States (220149) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000486)

**This page was last updated on** 17/02/2026

## Share this page

[Back to top](#main-content)